在1型糖尿病的学龄前儿童中,用时间在紧密的葡萄糖范围中作为促进健康的战略
Frida Sundberg1, Carmel E Smart2, John Samuelsson3,4
1Department of Paediatrics, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Diabetes care
|November 15, 2024
概括
狭窄范围的时间 (TITR) 是管理幼儿1型糖尿病的关键指标. 达到>50%的TITR对于患有1型糖尿病的学龄前儿童来说是一个现实的,促进健康的目标.
科学领域:
- 儿科 儿科 儿科
- 内分泌学 在内分泌学.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 儿童早期出现的1型糖尿病 (T1D) 存在长期高血糖症,并发症和认知障碍的风险,这是由于对发育中的大脑的影响.
- 评估胰岛素治疗的疗效需要葡萄糖值值,从而定义了时间在狭窄范围 (TITR) 作为衡量正常血糖的标准.
- 国际指导方针建议在T1D的学龄前儿童的范围中>70%的时间 (70-180 mg/dL) 或>50%的TITR (70-140 mg/dL).
研究的目的:
- 审查和讨论国际知识和经验,关于时间紧密范围 (TITR) 作为健康促进策略,为T1D学龄前儿童.
- 探索TITR在儿科糖尿病护理中的结构和个人层面的应用.
主要方法:
- 对国际文献和临床实践的审查,涉及儿童1型糖尿病管理的时间紧密范围 (TITR).
- 分析瑞典注册数据,表明7岁以下儿童的血糖控制.
- 讨论儿科糖尿病团队在设定和实现血糖目标方面的经验.
主要成果:
- 瑞典登记数据显示,超过50%的7岁以下儿童达到>50%的时间在紧密范围 (TITR).
- 在过去的二十年里,瑞典的儿科糖尿病小组一直专注于70-140 mg/dL (3.9-7.8 mmol/L) 的目标范围.
- 这项研究强调了在患有T1D的幼儿中实现显著的Time in Tight Range (TITR) 的可行性.
结论:
- 随着胰岛素治疗的进展,最大限度地提高正常血糖时间 (TITR) 是T1D儿童家庭的合理和可解释的目标.
- 对于那些能够接触到经验丰富的医疗团队和技术的儿童来说,一个现实的目标是至少达到50%的时间在紧密范围 (TITR).
- 密切范围的时间 (TITR) 作为一种有价值的健康促进策略,用于管理学龄前儿童的1型糖尿病.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Insulin: Dosing Regimen and Adverse Effects
146
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
146
Hypoglycemia and Glucagon
152
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
152
Diabetes: Management and Pharmacotherapy
236
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
236
Diabetes Mellitus: Overview and Type I Subtype
2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Diabetes: Symptoms, Diagnosis, and Complications
508
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
508


